Reported a net loss of $10,487,532 for the year ended December 31, 2025, an improvement from $12,497,805 in 2024. Revenue decreased by 79% to $1,928,998 in 2025 from $9,291,115 in 2024, primarily due to a 77% decrease in specimen count (from 23,139 to 5,425). The average selling price per specimen decreased by 11% from approximately $402 in 2024 to $356 in 2025. Accumulated deficit reached $82,350,149 as of December 31, 2025. Cash and cash equivalents increased significantly to $6,880,835 in 2025 from $1,878,408 in 2024, largely due to equity financing. Working capital improved from a deficiency of $2,182,488 in 2024 to a positive $723,284 in 2025. Identified a material weakness in internal control over financial reporting related to sales tax documentation, calculation, collection, reporting, and remittance. The company is not in compliance with Nasdaq's minimum bid price requirement ($1.00) as of November 19, 2025, and has until May 18, 2026, to regain compliance. Significant cost reductions were implemented, including an estimated 67% reduction in monthly compensation costs and 25% in technology costs from January 1, 2024, through December 31, 2025, compared to 2024. The company faces several legal proceedings, including claims from Focus Technology Solutions, Inc. ($489,572), Azenta US, Inc. ($651,262), and Krisbio, LLC ($266,380). A claim from Ellenoff Grossman & Schole, LLP ($425,684) was settled for $200,000 post-year-end.